Core Viewpoint - The article discusses the pharmaceutical traceability code scanning all-in-one machine, highlighting its importance in ensuring drug quality and compliance with traceability regulations in the pharmaceutical industry [2][9]. Market Size and Industry Landscape - According to QYResearch, the global market for pharmaceutical traceability code scanning all-in-one machines is projected to reach USD 470 million by 2032, with a compound annual growth rate (CAGR) of 7.3% in the coming years [3]. - Major manufacturers in the global market include Soman Technology, SUPOIN, iData, Shenzhen Youbuxun Technology Co., Ltd., and others [5][6]. Industry Chain Analysis - The industry chain consists of upstream hardware component suppliers, software developers, midstream device manufacturers, and downstream pharmaceutical distributors and retail pharmacies [8]. Industry Policy Analysis - Recent regulatory policies in China and the U.S. are accelerating the adoption of traceability code scanning devices, increasing demand for compliant integrated devices [9]. Trends in Smart Functionality - The integration of advanced AI capabilities for automatic error correction and IoT-based device monitoring is enhancing the efficiency and accuracy of scanning machines [10]. - The expansion of multi-modal code recognition capabilities allows devices to read various formats, improving their utility in logistics [10]. Industry Development Opportunities - Regulatory-driven demand for compliant devices is creating a significant market opportunity, especially in underdeveloped regions [12]. - The shift towards smart upgrades is prompting existing users to replace outdated devices with advanced models [12]. - Opportunities exist to extend the application of these devices to adjacent regulatory fields, such as medical devices and health supplements [12]. Data Value Extraction and Collaborative Service Opportunities - The ability of scanning devices to collect vast amounts of drug flow data presents opportunities for collaboration with pharmaceutical companies and regulatory bodies to provide value-added data services [13]. Industry Development Challenges - The industry faces high compliance and technical barriers, requiring significant investment in R&D and certification [14]. - Small pharmaceutical entities are under financial pressure to comply with regulations, which may hinder market penetration [14]. - Data interoperability issues between different systems can weaken the effectiveness of traceability efforts [14]. After-Sales Service and Maintenance Bottlenecks - Uneven distribution of after-sales service networks can lead to delays in equipment repair, posing compliance risks [15].

证券日报网讯 1月12日，新北洋在互动平台回答投资者提问时表示，截至2025年12月底，新北洋的股东 户数为48005户。 （文章来源：证券日报） ...

Core Viewpoint - The stock of Xinbeiyang has shown positive performance with a 2.05% increase on January 12, 2023, and a total market capitalization of 6.468 billion yuan, indicating strong investor interest and potential growth in the company's operations [1]. Group 1: Stock Performance - As of January 12, 2023, Xinbeiyang's stock price reached 7.98 yuan per share, with a trading volume of 1.66 billion yuan and a turnover rate of 2.69% [1]. - Year-to-date, the stock price has increased by 3.37%, with a 3.23% rise over the last five trading days, a 10.07% increase over the last 20 days, and a 5.00% increase over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Xinbeiyang reported a revenue of 1.982 billion yuan, representing a year-on-year growth of 16.82%, and a net profit attributable to shareholders of 61.09 million yuan, reflecting a significant increase of 56.26% [2]. - Since its A-share listing, Xinbeiyang has distributed a total of 1.579 billion yuan in dividends, with 351 million yuan distributed over the past three years [3]. Group 3: Shareholder Information - As of December 31, 2025, the number of shareholders for Xinbeiyang was 48,000, a decrease of 2.22% from the previous period, while the average number of circulating shares per person increased by 2.27% to 16,275 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the sixth largest, holding 6.2141 million shares as a new shareholder [3]. Group 4: Business Overview - Xinbeiyang, established on December 6, 2002, and listed on March 23, 2010, is based in Weihai, Shandong Province, and specializes in the research, production, sales, and service of intelligent devices and equipment [1]. - The company's main business revenue breakdown includes: intelligent self-service terminal products (26.79%), printing and scanning products (21.43%), service operations (14.55%), smart financial equipment (13.06%), key basic components (10.49%), intelligent logistics equipment (9.19%), and others (4.49%) [1].

（文章来源：证券日报） 证券日报网讯 1月5日，新北洋在互动平台回答投资者提问时表示，截至2025年12月底，新北洋的股东 户数为48005户。 ...

证券日报网讯12月24日，新北洋（002376）在互动平台回答投资者提问时表示，截至2025年11月底，新 北洋的股东户数为49096户。 ...

Core Viewpoint - The company has reported that its smart micro-super products have achieved a certain level of sales in the "trendy play" scenario, but the overall sales scale remains small, contributing minimally to the company's revenue and not significantly impacting its performance [1] Group 1 - The company is actively expanding its customer base related to the "trendy play" business [1] - The company advises investors to adhere to value investment principles and make rational decisions [1]

Core Viewpoint - The company, Xinbeiyang, is committed to a strategic framework of "one body, two wings, and eight major businesses," aiming for sustainable and predictable quality growth in its performance over the coming years [1] Group 1: Strategic Growth Curves - The first strategic growth curve focuses on printing and scanning products, smart self-service terminals, smart financial devices, and intelligent logistics equipment, which are expected to support stable revenue and profit growth over the next 2 to 3 years [1] - The second strategic growth curve includes new retail comprehensive operations, logistics automation sorting operations, and equipment comprehensive operation and maintenance services, which are targeted to create new rapid growth points for the company in the next 3 to 5 years [1] - The third strategic growth curve emphasizes key basic components, aiming to cultivate long-term competitive advantages and emerging growth areas for the company over the next 5 to 7 years [1] Group 2: International Market Expansion - The company is actively expanding into overseas markets, with rapid growth in overseas market revenue effectively supporting the overall performance and ensuring quality sustainable growth [1]

Core Viewpoint - New Beiyang (002376) is actively responding to strategic customer demands by undertaking the production verification task for "smart delivery robots," with initial sample deliveries successfully completed [1] Group 1: Company Developments - New Beiyang has begun the production verification of smart delivery robot prototypes, which are designed to provide efficient, precise, and safe unmanned delivery services in certain closed and semi-closed areas [1] - The current stage of prototype production verification is still in its early phases, indicating significant uncertainty [1] Group 2: Market Impact - The ongoing prototype production verification task is not expected to impact New Beiyang's current operating performance [1] - Investors are advised to remain cautious regarding investment risks associated with this early-stage project [1]

Group 1 - The company is actively responding to the strategic needs of major clients by undertaking the production verification task for "smart delivery robots" [1] - The smart delivery robots are designed to provide efficient, precise, and safe unmanned delivery services in certain closed or semi-closed areas [1] - The current stage of prototype production verification is still in its early phase, with significant uncertainties, and it will not impact the company's current operating performance [1]

Core Viewpoint - The company is actively responding to the needs of strategic major clients by undertaking the production verification task for "smart delivery robots," with initial successful delivery of test prototypes [1] Group 1: Company Developments - The company has successfully achieved the delivery of a small quantity of test prototypes for smart delivery robots [1] - The smart delivery robots are designed to provide efficient, precise, and safe unmanned delivery services in certain closed and semi-closed areas [1] - The current stage of prototype production verification is still in its early phase, indicating significant uncertainty [1] Group 2: Financial Impact - The ongoing prototype production verification task is not expected to impact the company's current operating performance [1]